[Articles] Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial

Journal content Created on 30 Jun 2026 The Lancet Oncology

• Details
• • All feed content
  • My feed content